Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Int J Cancer. 2011 Aug 24;130(11):2672–2684. doi: 10.1002/ijc.26269

Figure 3. Impact of vaccination coverage and screening coverage on reduction in the lifetime risk of cancer and the incremental cost-effectiveness ratio of vaccination followed by one screening per lifetime with one-visit HPV DNA testing (comparator: vaccine alone; cost per vaccinated girl: I$10), Uganda.

Figure 3

Colored vertical bars represent mean reduction in lifetime risk of cancer (on the primary y-axis) at different levels of vaccination coverage (25-75%, on the x-axis) and screening coverage (green, 25%; blue, 50%; pink, 75%). Error bars represent the range of uncertainty in cancer reduction based on the 50 top-fitting parameter sets. Lines with colors corresponding to level of screening coverage represent the incremental cost-effectiveness ratio (on the secondary y-axis) at different levels of vaccination coverage. The dashed black line represents a threshold of 30% cancer reduction. ICER=incremental cost-effectiveness ratio; YLS = years of life saved.